Capmatinib

Overview

Capmatinib is a tyrosine kinase inhibitor targeting the MET receptor, indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. It works by blocking the MET signaling pathways, which are active in various cancers.

API suppliers (3)

Suppliers of Capmatinib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• TAPI NL BV1 active DMF
• TAPI NL BV1 active DMF
• TAPI NL BV1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Capmatinib expires 21 Jul 2035 and exclusivity 5 May 2027. Generic API sourcing typically opens up once these lapse.

Therapeutic areas